Brand, in healthcare, is too easily mistaken for identity — a logo, a campaign, a reputation to manage. But brand is doing one thing: earning trust. Trust is brand made measurable — the one signal patients, clinicians, regulators and partners all read. That’s the North Star this diagnostic is built on.
The Government is abolishing NHS England.
The story underneath the abolition is the one healthcare hasn’t been telling itself.
Trust is the currency the whole reform now runs on — and almost no one is measuring it.
The Health Bill 2026–27 abolishes NHS England, folding the national commissioning body into the Department of Health and Social Care to cut bureaucracy and push decisions local. Alongside it, the 10-Year Health Plan — Fit for the Future — sets three shifts: hospital to community, analogue to digital, sickness to prevention. And “earned autonomy” means the first new Foundation Trusts are approved in 2026, with the ambition that by 2035 every NHS provider is one.
Earned autonomy is the line that matters. It makes trust the currency: the providers that can evidence safe, high-performing, well-governed care get freedom and budget; the ones that can’t get oversight. Integrated Health Organisations will soon hold the health budget for an entire population and answer for every service within it.
The market reads this as a reorganisation story. The sector should read it as something else: the first time in this cycle that the trust architecture connecting patients, clinicians, commissioners, regulators and the public has been forced into the live operating conversation — simultaneously, and at the exact moment the centre that used to hold it is being removed.
For a decade, healthcare’s trust battle has been fought on three terrains. Clarity: what does this organisation stand for — what care, what outcomes, what public-benefit case? Connection: do patients, clinicians, commissioners, regulators and the public see the same organisation? Confidence: is the intent matched by what is actually delivered — safely, equitably, on time? These three trust enablers are the operating geography most brand, comms, engagement and corporate-affairs leaders in healthcare now work inside.
And the bar these drivers are measured against keeps moving. Expectation here isn’t fixed — it is what each stakeholder group expects and increasingly needs, and events keep raising it. Measured against a rising bar, a steady score is already slipping. Where that bar is heading is read here from public signal alone, as a hypothesis — one a TrustOS Snapshot is built to test with primary stakeholder research.
In healthcare the bar moved the moment autonomy was tied to evidence. Patients, the CQC, commissioners and now the neighbourhood and Integrated Health Organisation structures no longer accept a stated commitment to safe, equitable care — they increasingly expect it evidenced, in something close to real time, as the condition of trust, funding and freedom. The promise has not changed; the standard it is read against has risen.
But the drivers sit on a foundation. The TrustOS methodology calls that foundation Integrity — and in healthcare, Integrity manifests as Clinical Trust: the duty of candour, the clinical governance, the safety culture and the honesty-when-things-go-wrong that the entire system is supposed to hold — and that successive public inquiries keep finding it did not.
The abolition of NHS England and the move to earned autonomy have just made it un-assumable.
Why “NHS England is abolished” is a sector story, not a structural one
When the body that guaranteed national consistency is removed and trust becomes the condition of autonomy, three things happen at once.
One. Every provider re-reads its own trust architecture against the bar earned autonomy now sets. The trusts, ICBs and emerging IHOs that can evidence safe, well-governed, equitable care — and the operating architecture that delivers it — will price differently in regulatory freedom, funding allocation, political risk and public confidence. The screening sweeps across the system as the first Foundation Trust approvals land.
Two. Patients, clinicians, the public and commissioners re-price the credibility of the system’s claim about what the NHS is for. A claim about “safe, universal care, free at the point of use” is read differently once the central architecture that assured consistency is dismantled and 42 ICBs, neighbourhood health centres and whole-population IHOs become the unit of trust. The Confidence cost is no longer measurable only in waiting lists; it is measurable in attendance, in workforce confidence, in public-inquiry exposure and in the political cost of a fragmentation the system cannot yet evidence it has thought through.
Three. Regulators, Government and the public re-set the bar on what they will permit and fund. The CQC’s assessment, the duty-of-candour test and the new earned-autonomy criteria convert “trust us” into a measurable condition. Future funding, autonomy and political licence will be read against the trust evidence in a way they have not previously been.
None of this is unique to any one trust, ICB, pharma company or private provider. All of it is now live for the rest of the sector — including the pharma, medtech and life-sciences companies whose entire NHS relationship runs through the same trust architecture.
The diagnostic — healthcare’s trust shape in 2026
Running the TrustOS methodology across the sector at composite level produces this picture.
Clarity — 67. High, and broadly stable. The mission is clear and widely held: safe, universal care, free at the point of use. The 10-Year Health Plan gives the system a shared, quantified narrative of where it is going — community, digital, prevention. Pharma and medtech articulate purpose and evidence well. Clarity is the highest of the three, and it is not where the sector loses ground in 2026.
Connection — 45. The sector’s weakest layer, and a structural one. The lived experience of a patient, their family, the clinician treating them, the GP referring them, the trust delivering care, the ICB commissioning it, the regulator inspecting it, the pharma or medtech supplier behind it, and the public funding it all read as different systems to the outside world. More than 200 trusts, 42 ICBs, emerging neighbourhoods and IHOs, two-plus regulators, and the primary / secondary / community / social-care splits produce inconsistent evidence at every level. The abolition of the centre widens that gap before it narrows it.
Confidence — 50. Where delivery strain and earned autonomy now meet. Waiting lists, safety inquiries, the analogue-to-digital transition, workforce pressure and the equity of access all sit on the Confidence axis — intent versus reality. Earned autonomy has just made this the layer that determines a provider’s freedom and funding.
Composite trust score: 54. In the same window as Social Care, and below Education’s 57. Healthcare is in one of the harder trust windows of this series — and the removal of NHS England has just lowered the floor under the consistency the public assumed.
Clinical Trust — how Integrity manifests for healthcare
The three enablers operate on a foundation. The canonical TrustOS foundation is Integrity. In healthcare, Integrity manifests as Clinical Trust: the architecture of safety, candour and governance that connects what the system promises — safe, honest, equitable care — to what patients actually receive, and to whether the system tells the truth when it falls short.
For most of the past decade, this foundation has been treated as a regulatory minimum — something the CQC inspects, not something the organisation evidences in its own operating rhythm. Safety owns incidents. Governance owns the board paper. Comms owns the reputation. The connective tissue between them — the trust architecture — has been presumed to follow from compliance, rarely tested in public until an inquiry forces it.
The abolition of the centre, the move to earned autonomy and the run of safety inquiries make the foundation visible — and prove three things about it.
1. Clinical Trust is architectural, not declarative.
A “safe, compassionate, honest” promise is now testable against safety data, candour outcomes, equity-of-access evidence and the lived experience of every stakeholder group. The organisation that can show — quarterly, evidenced, comparable — that its trust architecture is operating will lead the autonomy, funding and public conversation. The one that cannot will watch every safety event, every inspection and every inquiry land on top of an unmeasured foundation.
2. Clinical Trust is connected to the three drivers.
A Clarity claim about “putting patients first” rings hollow if it is not evidenced where patients actually experience care. A Connection claim about “one joined-up system” rings hollow when the trust, the ICB, the GP, the regulator and the supplier run from different evidence. A Confidence claim about safety rings hollow if the system cannot show its candour and governance in operation, not just on the board agenda.
3. The cost of an evidence-gap is non-linear once it compounds.
The first gap is a difficult inspection. The second is a coroner’s finding. The third is a public inquiry. The fourth is a loss of the autonomy, funding or political licence the organisation depends on. The gap compounds across every related front: safety, equity, workforce confidence and the supplier relationships that run through the same trust.
Where this lands across the three healthcare slices
NHS providers and systems. Acute trusts, mental-health and community providers, the new Foundation Trusts, the 42 ICBs, neighbourhood health centres and the first Integrated Health Organisations sit at the intersection of earned autonomy, the duty of candour, safety governance and the equity-of-access question. Clinical Trust is most exposed here, because care is the product.
Pharma and life sciences. AstraZeneca, GSK, Bayer, ViiV and the wider pharma sector sit in a different exposure profile. The trust battleground runs on the credibility of evidence, clinical-trial transparency, the access-and-pricing relationship with the NHS (the voluntary scheme / VPAG), and the reputational legacy the industry still carries. The NHS relationship runs entirely through trust.
Medtech, digital health and private care. Philips, Swisslog, the AI-diagnostics and digital-health vendors, the private hospital groups, AXA Health and the social-care-adjacent providers (CareTech) sit on a Confidence-gap defined by the analogue-to-digital shift, data trust, AI-in-diagnostics safety, and the increasingly visible private / NHS interface. The trust question here is whether the technology and the data behind care can be evidenced as safe.
The four operating moves
1. Make the trust signal quarterly, not inspection-cycle.
Annual CQC assessments, annual staff surveys and periodic inquiries are necessary but no longer sufficient. The signal that matters now is the trend line between cycles — by stakeholder, by service, by enabler — especially as earned autonomy raises the bar.
2. Make the system picture and the patient picture reconcile.
The Connection leak is the gap between what the organisation claims and what the patient, the clinician, the commissioner, the regulator and the supplier actually experience. The unlock is one instrument, deployed consistently across the system, that produces both board-level visibility and service-level granularity.
3. Give the comms and engagement leader cross-functional operating standing.
Brand, comms, engagement and corporate-affairs leaders in healthcare are increasingly asked to defend trust positions that are partly clinical, partly operational, partly political. The leverage move is to put a defensible operating signal next to every cross-functional conversation — with the medical director, the chief nurse, the ICB and the regulator.
4. Build the Clinical Trust architecture before the next autonomy or safety event forces it.
The next earned-autonomy decision, CQC framework or safety inquiry will land on an organisation that can either evidence its Clinical Trust — or assert it. The leaders who build the architecture in this window will spend 2028–2030 leading the trust conversation rather than defending it.
The window
The 2026–2027 window is the architectural window. The first Foundation Trust approvals are landing; the IHOs are forming; the CQC framework and the earned-autonomy criteria are being set; NHS England is being dismantled. The organisations that get the Clinical Trust architecture in place during this window will spend the next phase leading the trust conversation across patients, regulators, commissioners and the public.
None of this requires a new mission. The promise is already named — safe, universal, honest care. The proof points already exist across the system. What’s missing is the architecture that turns distributed evidence into trend, a fragmenting system into one signal, and quarterly delivery into inspection-ready, autonomy-ready and board-ready proof.
The question
For every brand, comms, engagement and corporate-affairs leader across the NHS, pharma, medtech and private health:
Can you show your Clinical Trust — across patients, clinicians, commissioners, regulators and the public — at the cadence earned autonomy now demands, without commissioning a new inquiry to find out?
If the answer is no, the next autonomy decision, the next inspection, the next safety event or the next public inquiry is the one that prices the gap. If the answer is yes, this window is the one your organisation’s trust position is built in.
— Dustin Lawrence, Founder, MissionCTRL